Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Blood (2023) 142 (Supplement 1): 6173.

https://doi.org/10.1182/blood-2023-186601

Published: 2023

Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford

Blood (2023) 142 (Supplement 1): 612.

https://doi.org/10.1182/blood-2023-185818

Published: 2023

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Blood (2022) 140 (Supplement 1): 10106–10107.

https://doi.org/10.1182/blood-2022-169882

Published: 2022

Journal Articles

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Blood (2021) 138 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2021-150177

Published: 2021

Journal Articles

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Blood (2021) 138 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2021-147771

Published: 2021

Journal Articles

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

Blood (2021) 137 (22): 3064–3078.

https://doi.org/10.1182/blood.2020005964

Published: 2021

Includes: Supplemental data

Journal Articles

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski, MD, Lasse H. Jakobsen, PhD, Graham P. Collins, MD DPhil, Kate Cwynarski, Veronika Bachanova, MD PhD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Mark Bower, MD, Alessia Dalla Pria, MD, Alexey Danilov, MD, Kevin A. David, MD, Catherine Diefenbach, MD, Fredrik Ellin, MD PhD, Narendranath Epperla, MDMS, Umar Farooq, MD, Tatyana A. Feldman, MD, Alina S. Gerrie, MD MPH, Deepa Jagadeesh, MDMPH, Manali Kamdar, MD MD, Reem Karmali, MDMSc, Shireen Kassam, MBBS, FRCPath, PhD, Vaishalee P. Kenkre, MD, Nadia Khan, MD, Andreas Klein, MD, Izidore S. Lossos, MD, Matthew A. Lunning, DO, FACP, Peter Martin, FRCPC, MD MS, Nicolas Martinex-Calle, Silvia Montoto, MD, Seema Naik, MD, Neil Palmisiano, MDMS, David Peace, MD, Elizabeth H Phillips, MBBS, BSc, Tycel J. Phillips, MD, Craig A. Portell, MD, Nishitha Reddy, MD, Anna Santarsieri, MBBS, Maryam Sarraf Yazdy, MD, Knut B. Smeland, Scott E. Smith, MD PhD, Stephen D. Smith, MD, Suchitra Sundaram, MD, Parameswaran Venugopal, MD, Adam Zayac, MD, Xiao-Yin Zhang, PhD, Catherine Zhu, Chan Yoon Cheah, MBBS, Tarec Christoffer El-Galaly, Andrew M. Evens, DO,MMSc

Blood (2020) 136 (Supplement 1): 46–49.

https://doi.org/10.1182/blood-2020-134985

Published: 2020

Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD

Blood (2016) 128 (22): 6.

https://doi.org/10.1182/blood.V128.22.6.6

Published: 2016

Journal Articles

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Elizabeth H Phillips, Amy A Kirkwood, Anthony Lawrie, Simon Rule, Russell Patmore, MRCP FRCPath, Ruth Pettengell, Cathy H Burton, Kirit M Ardeshna, Silvia Montoto, MD, Shankaranarayana Paneesha, Paul Smith, Katharina Wanek, Laura Clifton-Hadley, PhD BSc, David C. Linch, MD MRCP, MB BCh, BA, Andrew McMillan, PhD

Blood (2016) 128 (22): 1855.

https://doi.org/10.1182/blood.V128.22.1855.1855

Published: 2016

Journal Articles

Identification Of aHUS and Complement Mutations In Patients Presenting With Acute Thrombotic Microangiopathy

Elizabeth H Phillips, MD, John Connolly, MD, John-Paul Westwood, MD, Siobhan McGuckin, Daniel P Gale, MD, Tim H. J. Goodship, MD, David Kavanagh, MD, Marie A Scully, MD

Blood (2013) 122 (21): 1073.

https://doi.org/10.1182/blood.V122.21.1073.1073

Published: 2013

NARROW

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial

Identification Of aHUS and Complement Mutations In Patients Presenting With Acute Thrombotic Microangiopathy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only